Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to evaluate the effect of hyperbaric oxygen therapy (HBOT) on airway complications in post-lung transplant recipients with evidence of restricted levels of blood and oxygen in the airway tissue. Study subjects with extensive airway tissue damage in the early post-transplant period will be randomized to HBOT or usual care and followed clinically for 12 months following randomization. The investigators hypothesize that HBOT will decrease the number of airway complications in the treated subjects.


Clinical Trial Description

Hyperbaric oxygen therapy (HBOT) will be performed with the standard HBOT protocol used at Duke for the treatment of compromised grafts and flaps. This is 2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at atmospheric pressure of 2 once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician. The HBOT procedure used for this study will be identical to that used for clinical practice in the Duke University Health System Center for Hyperbaric Medicine and Environmental Physiology, including the oxygen that is used in the chamber. Patients will receive treatment through the regular clinical hyperbaric service. These are routine, not special, treatment sessions and they will receive them alongside other Duke University Medical Center patients being treated for other reasons. The medical grade oxygen used is a part of the Duke University Health System Center for Hyperbaric Medicine and Environmental Physiology hyperbaric chamber system. While the patients randomized to receive usual care will not undergo HBOT, both study groups will receive standard serial bronchoscopies for airway clearance and for the collection of bronchoalveolar lavage fluid for culture data, due to the high rate of infection in lung transplant patients. All subjects will undergo the standard surveillance bronchoscopies every 3 to 4 weeks (x3) for clearance of the exudate from the airway, as well as monitoring progression of the airway abnormalities. As participants in this study, an, endobronchial biopsy of the airway epithelium will be performed at the main carina to collect a sample of recipient epithelium as well as at the first subcarina for each donor lung. Three samples will be collected from each of the biopsy sites. These samples are small (1 to 2 mm) and are thought to have a minimal clinical risk of minor bleeding associated with the procedure. Biopsy will add roughly 3 minutes total to each procedure. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02363959
Study type Interventional
Source Duke University
Contact
Status Completed
Phase Phase 2
Start date February 2015
Completion date September 30, 2018

See also
  Status Clinical Trial Phase
Completed NCT01915082 - Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Phase 4
Completed NCT02744872 - Copenhagen Acute Renal Complications After Transplantations Study Group Phase 4
Withdrawn NCT02395393 - Confocal Fluorescence Microscopy of the Human Airways in Diagnostics of Lung Transplantation N/A
Completed NCT02262299 - European Trial of Pirfenidone in BOS, A European Multi-center Study Phase 2/Phase 3
Withdrawn NCT04415476 - Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS) Phase 2
Completed NCT01650545 - Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients Phase 1/Phase 2
Completed NCT01746914 - Morphofunctional Lung Analysis by PET and CT After Lung Transplantation N/A
Completed NCT01967953 - Ex-Vivo Lung Perfusion to Increase the Number of Organs for Transplantation Phase 1
Completed NCT01793246 - Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy in the Lung N/A
Recruiting NCT00177918 - Prospective Evaluations of Infectious Complication in Lung Transplant Recipients
Terminated NCT03473340 - Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD) Phase 2
Not yet recruiting NCT02380365 - QT-Prolongation in Lung Transplantation N/A